NASDAQ:ATRA Atara Biotherapeutics (ATRA) Stock Price, News & Analysis → We’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How) (From Paradigm Press) (Ad) Free ATRA Stock Alerts $0.53 -0.04 (-7.03%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$0.52▼$0.5750-Day Range$0.53▼$0.7852-Week Range$0.20▼$2.54Volume1.32 million shsAverage Volume2.29 million shsMarket Capitalization$63.68 millionP/E RatioN/ADividend YieldN/APrice Target$28.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Atara Biotherapeutics alerts: Email Address Atara Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside5,195.0% Upside$28.00 Price TargetShort InterestBearish9.65% of Shares Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$94,893 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.63) to ($0.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.99 out of 5 starsMedical Sector332nd out of 905 stocksBiological Products, Except Diagnostic Industry48th out of 150 stocks 3.0 Analyst's Opinion Consensus RatingAtara Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAtara Biotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Atara Biotherapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.65% of the outstanding shares of Atara Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverAtara Biotherapeutics has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Atara Biotherapeutics has recently decreased by 2.19%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAtara Biotherapeutics does not currently pay a dividend.Dividend GrowthAtara Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAtara Biotherapeutics has received a 75.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Atara Biotherapeutics is -0.87. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Atara Biotherapeutics this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for ATRA on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows5 people have added Atara Biotherapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atara Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $94,893.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of Atara Biotherapeutics is held by insiders.Percentage Held by Institutions70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Atara Biotherapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Atara Biotherapeutics are expected to decrease in the coming year, from ($0.63) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atara Biotherapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atara Biotherapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Atara Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Augury ResearchBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is currently auctioning off CITGO (the winning bid will be announced on July 22nd).Get all the details here. About Atara Biotherapeutics Stock (NASDAQ:ATRA)Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.Read More ATRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATRA Stock News HeadlinesMay 21, 2024 | insidertrades.comEric J. Hyllengren Sells 28,648 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) StockMay 21, 2024 | insidertrades.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Pascal Touchon Sells 81,506 SharesJune 7 at 4:01 PM | businesswire.comAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 5 at 4:01 PM | businesswire.comAtara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 29, 2024 | businesswire.comAtara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual MeetingMay 20, 2024 | finance.yahoo.comAtara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares RiseMay 20, 2024 | businesswire.comAtara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDAMay 11, 2024 | finance.yahoo.comAtara Biotherapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Atara Biotherapeutics on Strong Pipeline and Financial HealthMay 10, 2024 | investorplace.comATRA Stock Earnings: Atara Biotherapeutics Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | washingtonpost.comAtara Biotherapeutics: Q1 Earnings SnapshotMay 9, 2024 | businesswire.comAtara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational ProgressMay 3, 2024 | businesswire.comAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 5, 2024 | businesswire.comAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)March 28, 2024 | investorplace.comATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023March 28, 2024 | benzinga.comAtara Biotherapeutics: Q4 Earnings InsightsMarch 28, 2024 | finance.yahoo.comAtara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational ProgressMarch 16, 2024 | finance.yahoo.comATRA Apr 2024 0.500 callFebruary 29, 2024 | msn.comFDA clears Atara to begin Phase 1 study for lupus nephritis drugFebruary 29, 2024 | marketwatch.comAtara Biotherapeutics Gets FDA Clearance for ATA3219 IND ApplicationFebruary 29, 2024 | finance.yahoo.comAtara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T TherapyFebruary 28, 2024 | finance.yahoo.comAtara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care ConferenceFebruary 14, 2024 | finance.yahoo.comAtara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus NephritisFebruary 14, 2024 | businesswire.comAtara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus NephritisSee More Headlines Receive ATRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/07/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ATRA CUSIPN/A CIK1604464 Webwww.atarabio.com Phone(805) 623-4211FaxN/AEmployees334Year FoundedN/APrice Target and Rating Average Stock Price Target$28.00 High Stock Price Target$28.00 Low Stock Price Target$28.00 Potential Upside/Downside+5,195.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-276,130,000.00 Net Margins-671.70% Pretax Margin-671.65% Return on Equity-783.31% Return on Assets-121.73% Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.50 Sales & Book Value Annual Sales$8.57 million Price / Sales7.43 Cash FlowN/A Price / Cash FlowN/A Book Value($0.97) per share Price / Book-0.55Miscellaneous Outstanding Shares120,420,000Free Float115,961,000Market Cap$63.68 million OptionableOptionable Beta0.54 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Pascal Touchon D.V.M. (Age 61)President, CEO & Director Comp: $1.08MMr. K. Amar Murugan (Age 48)Executive VP & Chief Legal Officer Comp: $618.52kMr. Eric Hyllengren (Age 48)Executive VP & Chief Financial Officer Dr. Anhco Nguyen Ph.D. (Age 51)Executive VP and Chief Scientific & Technical Officer Alex ChapmanVice President of Corporate Communications & Investor RelationsMs. Jill Henrich (Age 61)Executive VP and Global Head of Regulatory Affairs & Quality Mr. Dan MaziaszExecutive VP & Chief Business OfficerMs. Rajani Dinavahi M.D.Senior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsCortexymeNASDAQ:CRTXBlack Diamond TherapeuticsNASDAQ:BDTXPoseida TherapeuticsNASDAQ:PSTXCentury TherapeuticsNASDAQ:IPSCAdaptimmune TherapeuticsNASDAQ:ADAPView All CompetitorsInsiders & InstitutionsRedmile Group LLCBought 156,863 shares on 5/16/2024Ownership: 7.693%Pascal TouchonSold 81,506 sharesTotal: $50,533.72 ($0.62/share)Anhco NguyenSold 42,899 sharesTotal: $26,597.38 ($0.62/share)Eric J HyllengrenSold 28,648 sharesTotal: $17,761.76 ($0.62/share)Price T Rowe Associates Inc. MDBought 4,903,159 shares on 5/15/2024Ownership: 4.117%View All Insider TransactionsView All Institutional Transactions ATRA Stock Analysis - Frequently Asked Questions Should I buy or sell Atara Biotherapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ATRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRA, but not buy additional shares or sell existing shares. View ATRA analyst ratings or view top-rated stocks. What is Atara Biotherapeutics' stock price target for 2024? 3 Wall Street research analysts have issued 1 year price objectives for Atara Biotherapeutics' stock. Their ATRA share price targets range from $28.00 to $28.00. On average, they expect the company's share price to reach $28.00 in the next year. This suggests a possible upside of 5,195.0% from the stock's current price. View analysts price targets for ATRA or view top-rated stocks among Wall Street analysts. How have ATRA shares performed in 2024? Atara Biotherapeutics' stock was trading at $0.5128 at the beginning of 2024. Since then, ATRA stock has increased by 3.1% and is now trading at $0.5288. View the best growth stocks for 2024 here. When is Atara Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our ATRA earnings forecast. How were Atara Biotherapeutics' earnings last quarter? Atara Biotherapeutics, Inc. (NASDAQ:ATRA) posted its earnings results on Thursday, May, 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.14. The biotechnology company had revenue of $27.36 million for the quarter, compared to the consensus estimate of $27 million. Atara Biotherapeutics had a negative net margin of 671.70% and a negative trailing twelve-month return on equity of 783.31%. What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO? 38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend. What other stocks do shareholders of Atara Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE). Who are Atara Biotherapeutics' major shareholders? Atara Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Redmile Group LLC (7.69%), Vanguard Group Inc. (4.16%), Price T Rowe Associates Inc. MD (4.12%), Acadian Asset Management LLC (2.19%), BNP Paribas Financial Markets (0.32%) and Delap Wealth Advisory LLC (0.03%). Insiders that own company stock include Amar Murugan, Anhco Nguyen, Carol Giltner Gallagher, Eric J Hyllengren, Jakob Dupont, Joe Newell, Kristin Yarema, Matthew K Fust, Pascal Touchon, Utpal Koppikar and William K Heiden. View institutional ownership trends. How do I buy shares of Atara Biotherapeutics? Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATRA) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.